secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLIFE SOLUTIONS INC (BLFS)
CIK:        0000834365
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001628280-23-028201
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLife Q2 revenue falls 3% to $39.5M; net loss $0.23/share; cuts FY guidance; plans freezer divest
--------------------------------------------------------------------------------

- Q2 2023 revenue $39.5M, down 3% YoY; cell processing up 22% but freezers down 26%.
- GAAP net loss $10.2M ($0.23 EPS); adjusted EBITDA -$1.2M vs +$1.2M a year ago.
- FY2023 revenue guidance lowered to $144M-$158M; previous cell processing guidance $89-93M now $65-74M.
- Committed to divest Stirling Ultracold and CBS freezer assets by end of 2023; focus on recurring higher-margin products.
- Pro forma H1 2023 revenue ex-freezers $51.5M; adj. gross margin 52%; adj. EBITDA margin 16-18%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/834365/000162828023028201/0001628280-23-028201-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/834365/000162828023028201/blfs-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-028201

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer